Search Results

There are 207852 results for: content related to: Psychiatric symptoms during interferon treatment for hepatitis C:experiences from a tertiary care hepatology centre

  1. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

    Journal of Viral Hepatitis

    Volume 19, Issue s2, May 2012, Pages: 1–26, I. M. Jacobson, J.-M. Pawlotsky, N. H. Afdhal, G. M. Dusheiko, X. Forns, D. M. Jensen, F. Poordad and J. Schulz

    Version of Record online : 8 MAR 2012, DOI: 10.1111/j.1365-2893.2012.01590.x

  2. You have free access to this content
    HCV Therapeutics: Approved Agents

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 1091A–1168A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26880

  3. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma

    Journal of Viral Hepatitis

    Volume 18, Issue 10, October 2011, Pages: e550–e560, T. Kawaoka, H. Aikata, S. Takaki, A. Hiramatsu, K. Waki, N. Hiraga, D. Miki, M. Tsuge, M. Imamura, Y. Kawakami, S. Takahashi, H. Ochi, H. Tashiro, H. Ohdan and K. Chayama

    Version of Record online : 23 MAY 2011, DOI: 10.1111/j.1365-2893.2011.01468.x

  4. You have free access to this content
    Poster Session 2: Hepatitis C: Approved Therapeutic Agents

    Hepatology

    Volume 60, Issue S1, October 2014, Pages: 659A–709A,

    Version of Record online : 1 OCT 2014, DOI: 10.1002/hep.27516

  5. The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 34, Issue 2, February 2014, Pages: 185–201, Marina Kawaguchi-Suzuki and Reginald F. Frye

    Version of Record online : 30 SEP 2013, DOI: 10.1002/phar.1349

  6. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response

    Journal of Viral Hepatitis

    Volume 19, Issue 5, May 2012, Pages: 332–340, P. J. Clark, A. J. Thompson, M. Zhu, D. M. Vock, Q. Zhu, D. Ge, K. Patel, S. A. Harrison, T. J. Urban, S. Naggie, J. Fellay, H. L. Tillmann, K. Shianna, S. Noviello, L. D. Pedicone, R. Esteban, P. Kwo, M. S. Sulkowski, N. Afdhal, J. K. Albrecht, D. B. Goldstein, J. G. McHutchison, A. J. Muir and for the IDEAL investigators

    Version of Record online : 22 FEB 2012, DOI: 10.1111/j.1365-2893.2011.01553.x

  7. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation

    Journal of Gastroenterology and Hepatology

    Volume 27, Issue 9, September 2012, Pages: 1467–1472, Tomokazu Kawaoka, Shoichi Takahashi, Shintaro Takaki, Akira Hiramatsu, Koji Waki, Nobuhiko Hiraga, Daiki Miki, Masataka Tsuge, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Takashi Onoe, Hirotaka Tashiro, Hideki Ohdan and Kazuaki Chayama

    Version of Record online : 21 AUG 2012, DOI: 10.1111/j.1440-1746.2012.07129.x

  8. You have free access to this content
    Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection

    Alimentary Pharmacology & Therapeutics

    Volume 40, Issue 6, September 2014, Pages: 657–675, S. Saab, S. C. Gordon, H. Park, M. Sulkowski, A. Ahmed and Z. Younossi

    Version of Record online : 28 JUL 2014, DOI: 10.1111/apt.12871

  9. You have free access to this content
    Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients

    Hepatology

    Volume 55, Issue 1, January 2012, Pages: 39–48, Birgit Edlich, Golo Ahlenstiel, Aintzane Azpiroz Zabaleta, Jonathan Stoltzfus, Mazen Noureddin, Elisavet Serti, Jordan J. Feld, T. Jake Liang, Yaron Rotman and Barbara Rehermann

    Version of Record online : 14 NOV 2011, DOI: 10.1002/hep.24628

  10. Therapy for hepatitis C genotype 3: moving forward

    Journal of Viral Hepatitis

    Volume 22, Issue 9, September 2015, Pages: 683–690, M. Buti, J. Llaneras, M. Riveiro-Barciela and R. Esteban

    Version of Record online : 13 MAY 2015, DOI: 10.1111/jvh.12419

  11. Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy

    Journal of Gastroenterology and Hepatology

    Volume 27, Issue 9, September 2012, Pages: 1461–1466, Hideyuki Nomura, Yugo Miyagi, Hironori Tanimoto, Nobuyuki Yamashita, Kiyoaki Ito, Naohiko Masaki and Masashi Mizokami

    Version of Record online : 21 AUG 2012, DOI: 10.1111/j.1440-1746.2012.07171.x

  12. You have full text access to this OnlineOpen article
    Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

    Journal of Viral Hepatitis

    Volume 19, Issue 2, February 2012, Pages: e134–e142, N. Hayashi, T. Okanoue, H. Tsubouchi, J. Toyota, K. Chayama and H. Kumada

    Version of Record online : 8 NOV 2011, DOI: 10.1111/j.1365-2893.2011.01528.x

  13. You have free access to this content
    Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects

    Journal of Gastroenterology and Hepatology

    Volume 29, Issue 8, August 2014, Pages: 1574–1581, Eric J Lawitz and Fernando E Membreno

    Version of Record online : 29 JUL 2014, DOI: 10.1111/jgh.12632

  14. You have free access to this content
    Poster Session 2: Hepatitis C: Therapeutics (Approved Agents)

    Hepatology

    Volume 62, Issue S1, October 2015, Pages: 714A–807A,

    Version of Record online : 7 OCT 2015, DOI: 10.1002/hep.28228

  15. You have free access to this content
    Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial

    Hepatology

    Volume 57, Issue 6, June 2013, Pages: 2155–2163, Mark S. Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, Tarik Asselah, Jean-Michel Pawlotsky, Stephen D. Shafran, Stanislas Pol, Stefan Mauss, Dominique Larrey, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann and Wulf O. Böcher

    Version of Record online : 12 JUN 2013, DOI: 10.1002/hep.26386

  16. You have free access to this content
    Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial

    Hepatology

    Volume 57, Issue 6, June 2013, Pages: 2143–2154, Mark S. Sulkowski, Tarik Asselah, Jacob Lalezari, Peter Ferenci, Hugo Fainboim, Barbara Leggett, Fernando Bessone, Stefan Mauss, Jeong Heo, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann and Wulf O. Böcher

    Version of Record online : 12 JUN 2013, DOI: 10.1002/hep.26276

  17. You have free access to this content
    Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial

    Hepatology

    Volume 57, Issue 3, March 2013, Pages: 974–984, Mark S. Sulkowski, Fred Poordad, Michael P. Manns, Jean-Pierre Bronowicki, K. Rajender Reddy, Stephen A. Harrison, Nezam H. Afdhal, Heather L. Sings, Lisa D. Pedicone, Kenneth J. Koury, Vilma Sniukiene, Margaret H. Burroughs, Janice K. Albrecht, Clifford A. Brass, Ira M. Jacobson and for the SPRINT-2 Trial Investigators

    Version of Record online : 11 FEB 2013, DOI: 10.1002/hep.26096

  18. You have free access to this content
    Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice

    Alimentary Pharmacology & Therapeutics

    Volume 29, Issue 9, May 2009, Pages: 1000–1010, J.-F. YANG, M.-Y. HSIEH, N.-J. HOU, C.-Y. DAI, J.-F. HUANG, Z.-Y. LIN, S.-C. CHEN, M.-Y. HSIEH, L.-Y. WANG, W.-L. CHUANG and M.-L. YU

    Version of Record online : 7 FEB 2009, DOI: 10.1111/j.1365-2036.2009.03957.x

  19. Rapid reduction of hepatitis C virus-Core protein in the peripheral blood improve the immunological response in chronic hepatitis C patients

    Hepatology Research

    Volume 41, Issue 12, December 2011, Pages: 1153–1168, Yasuteru Kondo, Yoshiyuki Ueno, Yuta Wakui, Masashi Ninomiya, Eiji Kakazu, Jun Inoue, Koju Kobayashi, Noriyuki Obara and Tooru Shimosegawa

    Version of Record online : 26 SEP 2011, DOI: 10.1111/j.1872-034X.2011.00878.x

  20. Thyroid dysfunction in a UK hepatitis C population treated with interferon-α and ribavirin combination therapy

    Clinical Endocrinology

    Volume 73, Issue 2, August 2010, Pages: 249–256, Seán J. Costelloe, Nancy Wassef, Josephine Schulz, Tina Vaghijiani, Catherine Morris, Stephen Whiting, Michael Thomas, Geoffrey Dusheiko, Michael Jacobs and Mark P. J. Vanderpump

    Version of Record online : 10 FEB 2010, DOI: 10.1111/j.1365-2265.2010.03785.x